Zhuhai Kinhoo Pharmaceutical Co. Ltd.

Main purpose: Using the Iguratimod tablets (specification: 25 mg) of Jinhong Pharmaceutical Co., Ltd. as the test preparation and the Iguratimod tablets (trade name: Edexin®, specification: 25 mg) of Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation, according to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: Using the Iguratimod tablets (specification: 25 mg) of Jinhong Pharmaceutical Co., Ltd. as the test preparation and the Iguratimod tablets (trade name: Edexin®, specification: 25 mg) of Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation, according to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To compare the differences in the absorption extent and absorption rate of loxoprofen sodium patch (100 mg/patch (10 cm×14 cm)) provided by Jinhong Pharmaceutical Co., Ltd. and loxoprofen sodium patch (specification: 100 mg/patch (10 cm×14 cm)) certified by Lead Chemical Co., Ltd. in Chinese healthy population under fasting administration conditions using a single-center, randomized, open, two-drug, two-period crossover, fasting trial design, and evaluate bioequivalence. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the adhesion of the test preparation and the reference preparation during medication in Chinese healthy subjects; 3) To evaluate the skin reactivity of the test preparation and the reference preparation in Chinese healthy subjects.